Last updated: July 28, 2026
What is Eagle Pharmaceuticals, Inc. v. Hospira, Inc. 1:21-cv-01619 about?
Answer: The case is a Delaware federal patent infringement action under the Hatch-Waxman Act in which Eagle alleges Hospira infringed one or more patents listed in the FDA Orange Book for the relevant Eagle drug, based on Hospira’s ANDA filing.
Case identification and procedural footprint
- Court/Docket: U.S. District Court for the District of Delaware, No. 1:21-cv-01619
- Parties: Eagle Pharmaceuticals, Inc. (plaintiff) vs. Hospira, Inc. (defendant)
- Patent dispute context: ANDA-based infringement allegations tied to Orange Book listings
What Eagle must prove in an ANDA infringement case
For an ANDA case like this, Eagle’s infringement burden typically centers on:
- Claim construction of the asserted patent claims
- Comparison of the ANDA product’s proposed composition, formulation, and/or method-of-use to the claim elements
- Establishing infringement by a pre-approval “therapeutic” product profile (as permitted in ANDA litigation practice)
- Addressing Hospira’s defenses on validity and enforceability
Which patents were asserted in Eagle v. Hospira (1:21-cv-01619)?
Answer: The asserted patent list is not available in the provided information, so it cannot be enumerated accurately.
How to interpret “asserted patents” in Hatch-Waxman filings
In Hatch-Waxman cases, the complaint typically identifies:
- The Orange Book patents asserted as infringed
- Whether infringement theories are based on composition/formulation, process, or method-of-use claims
- The specific ANDA paragraph(s) (e.g., Paragraph IV) triggering the suit’s timing and remedies
Why patent identification is critical to the economics of the case
Without the asserted patent numbers and claims, any assessment of:
- likely win/loss trajectory,
- injunction likelihood,
- expected damages or settlement value,
- and launch-date exposure
would be speculative.
What is the litigation timeline for Eagle v. Hospira 1:21-cv-01619 (filing, service, motions, trial dates)?
Answer: The timeline beyond docket number and year is not available in the provided information, so it cannot be reconstructed accurately.
Typical milestone sequence in ANDA patent cases
A complete case timeline normally covers:
- Complaint filing and service
- Answer and counterclaims
- Scheduling order (Markman dates, expert deadlines, pretrial)
- Claim construction rulings
- Summary judgment and Daubert motions (if any)
- Trial and post-trial remedies
- Appeals (if any)
What legal standards apply in Eagle’s ANDA patent infringement case against Hospira?
Answer: The case follows Hatch-Waxman § 271(e)(2) framework, with conventional patent infringement and validity/unenforceability standards governed by Federal Circuit law.
Infringement under § 271(e)(2)
Eagle’s claim is typically built around whether Hospira’s ANDA submission (and proposed commercial manufacture/use) would infringe the asserted claims if made and used/sold within the U.S. after approval.
Validity and enforceability defenses
Hospira’s defenses in ANDA patent suits usually include:
- Non-infringement (product does not meet claim limitations)
- Invalidity (anticipation, obviousness, lack of written description/enablement, indefiniteness)
- Indefiniteness affects enforceability of claim scope
- Inequitable conduct / unenforceability (if pled and supported)
Has Hospira filed a Paragraph IV certification in this case?
Answer: The specific certification paragraph and the ANDA notice details are not available in the provided information, so the Paragraph IV status cannot be stated.
Why certification paragraph drives the remedies clock
In Hatch-Waxman suits:
- A Paragraph IV certification can trigger the 45-day notice-to-sue and automatic statutory frameworks.
- The timing determines potential launch design-around windows and settlement leverage.
What is the status of the case now (settled, dismissed, pending, appeal)?
Answer: The current disposition and any settlement or judgment status are not available in the provided information.
How strong is Eagle’s patent estate in this litigation (claim scope, typical enforceability risks)?
Answer: Without the asserted patents and claim sets, an evaluation of strength cannot be performed accurately.
Common factors that determine enforcement strength in Orange Book disputes
When asserted claims are known, analysts typically weigh:
- claim breadth and how it maps to the ANDA product profile
- whether the asserted claims are composition/formulation vs. method-of-use
- whether the claims are likely vulnerable to obviousness over known prior art
- prosecution history estoppel and disclaimer risk
- enablement and written description support in the specification
- whether prior litigation involving the same family indicates survivability
What are the generic entry risks for Hospira if Eagle wins injunction?
Answer: The injunction and launch risk cannot be quantified without knowing (1) the asserted patents (including whether any are listed as blocking patents) and (2) the procedural posture and any stays.
Typical remedies structure in Hatch-Waxman cases
If a court finds infringement and rejects validity defenses:
- injunctive relief may block approval and launch during the relevant patent term (subject to FDA approval mechanics)
- settlement often occurs before final judgment via stipulated dates or license agreements
Could a biosimilar or 505(b)(2) pathway affect this dispute?
Answer: The pathway type is not available in the provided information, so biosimilar/505(b)(2) relevance cannot be determined.
How does this case fit into Eagle’s broader strategy against generic entrants?
Answer: The docket indicates Eagle is enforcing patent rights against a generics entrant. Without asserted-patent and product identifiers, this cannot be mapped to a specific Eagle product portfolio and enforcement pattern.
What a portfolio view normally requires
A strategic comparison usually includes:
- recurring defendants
- repeated asserted patent families
- whether settlements are license-based or date-based
- whether Eagle uses enforcement as a leverage tool for re-packaging, line extensions, or supply agreements
Key Takeaways
- Case type: Hatch-Waxman ANDA-based patent infringement action, U.S. District Court (D. Del.), No. 1:21-cv-01619.
- Issue: Eagle alleges Hospira infringed one or more Orange Book-listed patents tied to Hospira’s ANDA entry strategy.
- Missing for analysis: asserted patent identities, claim numbers, and the procedural disposition are not included in the provided information; without them, litigation merits, injunction likelihood, and generic-entry timelines cannot be stated.
FAQs
-
What triggers a Hatch-Waxman infringement suit like Eagle v. Hospira?
A Paragraph IV (or similar) certification coupled with Orange Book patent listing and the statutory notice-to-sue mechanism.
-
What happens to FDA approval if a court issues an injunction in an ANDA patent case?
FDA typically must withhold approval consistent with the injunction against the relevant product/patent.
-
How do claim construction rulings usually affect ANDA patent cases?
They narrow or broaden the meaning of claim terms, often flipping infringement or invalidity outcomes.
-
Why do method-of-use patents matter in ANDA litigation more than composition patents?
Method-of-use claims can hinge on labeling, prescribing instructions, and intended use evidence tied to the proposed ANDA product profile.
-
What settlement forms are common in Hatch-Waxman patent cases?
Stipulated dismissal with agreed launch dates, covenant-not-to-sue agreements, or patent licenses with defined royalty/term structures.
References
- U.S. District Court for the District of Delaware. Eagle Pharmaceuticals, Inc. v. Hospira, Inc., No. 1:21-cv-01619.
